Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization

References

• Global Initiative for Chronic Obstructive Lung DiseaseGOLD 2017 Global Strategy for the Diagnosis Management and Prevention of COPD Available from: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Accessed September 6, 2018
   Google Scholar
• DorseyKGradyJDesairNCenters Medicare Medicaid Services20152015 Condition-Specific Measures Updates and Specifications Report Hospital-Level 30-Day Risk-Standardized Readmission Measures Available from: https://www.qualitynet.org/dcs/BlobServer?blobkey=id&blobnocache=true&blobwhere=1228890435217&blobheader=multipart%2Foctetstream&blobheadername1=Content-Disposition&blobheadervalue1=attachment%3Bfilename%3DRdmn_AMIHFPNCOPDSTK_Msr_UpdtRpt.pdf&blobcol=urldata&blobtable=MungoBlobsAccessed September 7, 2018
   Google Scholar
• Canadian Institute for Health InformationOttawa, ONCIHI2012All-Cause Readmission to Acute Care and Return to the Emergency Department Available from: https://secure.cihi.ca/free_products/Readmission_to_acutecare_en.pdfAccessed September 7, 2018
   Google Scholar
• BafadhelMPavordIDRussellREKEosinophils in COPD: just another biomarker?Lancet Respir Med20175974775928601554
   PubMed Web of Science ®Google Scholar
• BafadhelMMckennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med2011184666267121680942
   PubMed Web of Science ®Google Scholar
• GeorgeLBrightlingCEEosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary diseaseTher Adv Chronic Dis201671345126770668
   PubMed Web of Science ®Google Scholar
• SivaRGreenRHBrightlingCEEosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trialEur Respir J200729590691317301099
   PubMed Web of Science ®Google Scholar
• BafadhelMDaviesLCalverleyPMAaronSDBrightlingCEPavordIDBlood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysisEur Respir J201444378979124925917
   PubMed Web of Science ®Google Scholar
• CouillardSLarivéePCourteauJVanasseAEosinophils in COPD Exacerbations Are Associated With Increased ReadmissionsChest2017151236637327746201
   PubMed Web of Science ®Google Scholar
• HasegawaKCamargoCAPrevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPDRespirology201621476176426699685
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• SiddiquiSHGuasconiAVestboJBlood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary DiseaseAm J Respir Crit Care Med2015192452352526051430
   PubMed Web of Science ®Google Scholar
• PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPDThorax201671211812526585525
   PubMed Web of Science ®Google Scholar
• BafadhelMGreeningNJHarvey-DunstanTCBlood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPDChest2016150232032826851799
   PubMed Web of Science ®Google Scholar
• BafadhelMPetersonSde BlasMAPredictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trialsLancet Respir Med20186211712629331313
   PubMed Web of Science ®Google Scholar
• Vedel-KroghSNielsenSLangePVestboJNBBlood Eosinophils and Exacerbations in Chronic ObstructiveAm J Respir Crit Care Med2016193996597426641631
   PubMed Web of Science ®Google Scholar
• PrinsHJDuijkersRLutterRBlood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPDRespir Med201713111812428947018
   PubMed Web of Science ®Google Scholar
• DumanDAksoyECoban AgcaMAgcaMCThe utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophiliaInt J Chron Obstruct Pulmon Dis20151012469247826648709
   PubMed Web of Science ®Google Scholar
• ThornGWRenoldAEWilsonDLClinical studies on the activity of orally administered cortisoneN Engl J Med19512451554955514875208
   PubMed Web of Science ®Google Scholar
• SuissaSdell’anielloSErnstPLong-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortalityThorax2012671195796322684094
   PubMed Web of Science ®Google Scholar
• HoTWTsaiYJRuanSYIn-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based studyPLoS One2014912e11486625490399
   PubMed Web of Science ®Google Scholar
• D’HooreWBouckaertATilquinCD’HooreWBouchaertATilquinCPractical considerations on the use of the Charlson comorbidity index with administrative data basesJ Clin Epidemiol19964912142914338991959
   PubMed Web of Science ®Google Scholar
• Serafino-AgrusaLScichiloneNSpataforaMBattagliaSBlood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: A case-control studyPulm Pharmacol Ther20163737899426996272
   PubMed Web of Science ®Google Scholar
• SaltürkCKarakurtZAdiguzelNDoes eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit?Int J Chron Obstruct Pulmon Dis20151011837184626392758
   PubMed Web of Science ®Google Scholar
• Rahimi-RadMHAsgariBHosseinzadehNEishiAEosinopenia as a Marker of Outcome in Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseMaedica2015101101326225143
   PubMedGoogle Scholar
• HollandMAlkhalilMChandromouliSJanjuaABaboresMEosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary diseaseRespirology201015116516719947999
   PubMed Web of Science ®Google Scholar
• BafadhelMMckennaSTerrySBlood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trialAm J Respir Crit Care Med20121861485522447964
   PubMed Web of Science ®Google Scholar
• PavordIDChanezPCrinerGJMepolizumab for Eosinophilic Chronic Obstructive Pulmonary DiseaseN Engl J Med20173771613162928893134
   PubMed Web of Science ®Google Scholar
• HastieATMartinezFJCurtisJLAssociation of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohortLancet Respir Med201751295696729146301
   PubMed Web of Science ®Google Scholar
• BrightlingCEBleeckerERPanettieriRABenralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a studyLancet Respir Med201421189190125208464
   PubMed Web of Science ®Google Scholar
• AstraZeneca2018Update on TERRANOVA Phase III trial for Fasenra in chronic obstructive pulmonary disease Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-terranova-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-30052018.html. Accessed July 9, 2018
   Google Scholar